Format

Send to

Choose Destination

See 1 citation found by title matching your search:

J Neurotrauma. 2017 Oct 1;34(19):2823-2832. doi: 10.1089/neu.2016.4852. Epub 2017 Jun 16.

Recovery from Coma Post-Cardiac Arrest Is Dependent on the Orexin Pathway.

Author information

1
1 Department of Neurology, School of Medicine, University of California , Irvine, California.
2
2 Department of Anatomy & Neurobiology, School of Medicine, University of California , Irvine, California.
3
3 Reeve-Irvine Research Center, School of Medicine, University of California , Irvine, California.

Abstract

Cardiac arrest (CA) affects >550,000 people annually in the United States whereas 80-90% of survivors suffer from a comatose state. Arousal from coma is critical for recovery, but mechanisms of arousal are undefined. Orexin-A, a hypothalamic excitatory neuropeptide, has been linked to arousal deficits in various brain injuries. We investigated the orexinergic system's role in recovery from CA-related neurological impairments, including arousal deficits. Using an asphyxial CA and resuscitation model in rats, we examine neurological recovery post-resuscitation in conjunction with changes in orexin-A levels in cerebrospinal fluid (CSF) and orexin-expressing neurons. We also conduct pharmacological inhibition of orexin post-resuscitation. We show that recovery from neurological deficits begins between 4 and 24 h post-resuscitation, with additional recovery by 72 h post-resuscitation. Orexin-A levels in the CSF are lowest during periods of poorest arousal post-resuscitation (4 h) and recover to control levels by 24 h. Immunostaining revealed that the number of orexin-A immunoreactive neurons declined at 4 h post-resuscitation, but increased to near normal levels by 24 h. There were no significant changes in the number of neurons expressing melanin-concentrating hormone, another neuropeptide localized in similar hypothalamus regions. Last, administration of the dual orexin receptor antagonist, suvorexant, during the initial 24 h post-resuscitation, led to sustained neurological deficits. The orexin pathway is critical during early phases of neurological recovery post-CA. Blocking this early action leads to persistent neurological deficits. This is of considerable clinical interest given that suvorexant recently received U.S. Food and Drug Administration approval for insomnia treatment.

KEYWORDS:

arousal; cardiac arrest; coma; neurological recovery; orexin

PMID:
28447885
PMCID:
PMC5647501
DOI:
10.1089/neu.2016.4852
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center